A Phase I Pharmacokinetic Trial of LY231514 [pemetrexed] Administered Intravenously Every 3 Weeks in Advanced Cancer Patients With Varying Degrees of Renal Function
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2005
At a glance
- Drugs Pemetrexed (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 27 Sep 2005 New trial record.